Top
Glycogen Storage Disease Type Ia (GSDIa) - Healing Genes
1348
post-template-default,single,single-post,postid-1348,single-format-standard,mkdf-bmi-calculator-1.0,mkd-core-1.1.1,tribe-no-js,wellspring-ver-1.8,mkdf-smooth-page-transitions,mkdf-ajax,mkdf-grid-1300,mkdf-blog-installed,mkdf-header-standard,mkdf-no-behavior,mkdf-default-mobile-header,mkdf-sticky-up-mobile-header,mkdf-dropdown-slide-from-bottom,mkdf-full-width-wide-menu,mkdf-search-dropdown,elementor-default,elementor-template-full-width,elementor-kit-3486,elementor-page-2540

Glycogen Storage Disease Type Ia (GSDIa)

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)

A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6- Phosphatase (G6Pase) in Adults With Glycogen Storage Disease Type Ia (GSDIa)


Phase 1

DESCRIPTION:

Doctors at research locations in CT, MI, and TX seek adult patients with Glycogen Storage Disease Type Ia (GSDIa) to trial a genetic therapy called DTX401. This therapy uses a disabled virus to transfer a functional copy of the gene for enzyme glucose-6-phosphatase-α, to improve the patients’ ability to regulate blood sugar (glucose).

The study will require a single IV infusion of DTX401, then follow up for a year that includes a fasting challenge with several blood draws.


PATIENT MUST:

  • Be male and 18 years or older
  • Documented GSDIa with confirmation by molecular testing
  • Patient’s GSDIa disease is stable as evidenced by no hospitalization for severe hypoglycemia during the 4-week period preceding the screening visit
  • Not have received a liver transplant, including hepatocyte cell therapy/transplant

THE STUDY INVOLVES:

  1. Screening before the treatment.
  2. A single infusion of DTX401 will be administered.
  3. Monitoring of the patient for a few hours after dosing, then minimal follow up for the next 2 years.

LOCATIONS AND CONTACTS:
The three study site locations are in CT, MI, and TX:
UCONN Health in Farmington, CT, Map.
Michigan Medicine University of Michigan in Ann Arbor, MI, Map.
UT Health – McGovern Medical School in Houston, TX, Map.
 
Contact:
Patient Advocacy  |  1-415-483-8800  |  [email protected]
HCPs Contact  |  1-888-756-8657  |  [email protected]
 
SPONSOR INFORMATION:
Ultragenyx Pharmaceutical Inc
 
Or go online:
https://clinicaltrials.gov/ct2/show/NCT03517085

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader